These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35402130)

  • 21. Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma.
    Tanriverdi O; Ates S; Sandal KK; Uylas S; Bosna IC; Alkan A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1765-1768. PubMed ID: 32164490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma.
    Narukawa T; Hongo F; Fujihara A; Ueno A; Matsugasumi T; Ukimura O
    Case Rep Oncol; 2020; 13(1):249-254. PubMed ID: 32308585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
    Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
    Front Immunol; 2022; 13():984132. PubMed ID: 36189265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.
    Pwint TP; Macaulay V; Roberts IS; Sullivan M; Protheroe A
    Urol Oncol; 2011; 29(6):821-4. PubMed ID: 19962921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A Case of Pericardial Effusion Induced by Nivolumab for Metastatic Renal Cell Carcinoma].
    Fukae S; Tanaka R; Yoshinaga M; Kawamura N; Nakagawa M; Tanigawa G; Tsutahara K; Takao T; Yamaguchi S
    Hinyokika Kiyo; 2019 Aug; 65(8):329-332. PubMed ID: 31501401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
    Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
    Noguchi G; Tsutsumi S; Yasui M; Ohtake S; Umemoto S; Nakaigawa N; Yao M; Kishida T
    BMC Urol; 2018 Apr; 18(1):26. PubMed ID: 29669553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed nivolumab-induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case.
    Todo M; Kondo H; Hayashi T; Masuda T; Okabe T; Kaneko G; Oyama M; Shirotake S; Nishimoto K
    IJU Case Rep; 2019 Sep; 2(5):272-275. PubMed ID: 32743435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
    Ucar G; Acikgoz Y; Ergun Y; Bal O; Yilmaz M; Karakaya S; Akdeniz N; Kostek O; Aydin Isak O; Yazici Sener G; Dirikoc M; Aktürk Esen S; Dogan M; Uncu D
    Cureus; 2020 Sep; 12(9):e10525. PubMed ID: 33094066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status and future perspectives of immunotherapy against urothelial and kidney cancer.
    Kobayashi T; Takeuchi A; Nishiyama H; Eto M
    Jpn J Clin Oncol; 2021 Oct; 51(10):1481-1492. PubMed ID: 34389866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [RENAL CELL CARCINOMA METASTASIS TO BLADDER DURING MOLECULAR TARGETED THERAPY WITH PAZOPANIB: REPORT OF TWO CASES].
    Maruo K; Takahashi A; Tabata H; Takayanagi A; Takagi Y
    Nihon Hinyokika Gakkai Zasshi; 2020; 111(2):58-61. PubMed ID: 33883361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis.
    Hisano M; Kato R; Itamochi H; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Baba T; Obara W
    IJU Case Rep; 2020 Sep; 3(5):185-188. PubMed ID: 32914070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
    Perego G; Barzaghi P; Vavassori I; Petrelli F
    Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Doehn C; Gschwend JE; Kuczyk MA
    Aktuelle Urol; 2019 Sep; ():. PubMed ID: 31486061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
    Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
    Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.